NCT05039736View on ClinicalTrials.gov

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 24, 2023

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Hepatocellular CarcinomaLiver Cancer
Interventions
DRUG

Cabozantinib

Given by PO

DRUG

Nivolumab

Given by IV

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05039736 - A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | Biotech Hunter | Biotech Hunter